Are Endocrine Disrupting Chemicals Increasing Health Costs?

Research published in The Lancet (October 17, 2016; doi:10.1016/S2213-8587(16)30275-3) examined the health and economic burden associated with endocrine-disrupting chemicals (EDCs). The authors analyzed how differences in regulatory policies between the United States and the European Union influence population exposure, disease burden, and associated medical costs.

Because exposure to endocrine-disrupting chemicals varies substantially between the United States and Europe, largely due to differences in chemical regulation, the authors used these contrasts to estimate disease prevalence and economic impact attributable to EDC exposure. Their analysis suggested that EDC-related disease costs exceed 1% of gross domestic product (GDP) in both regions, with a markedly higher burden in the United States.

In the United States, EDC exposure was estimated to contribute to disease and dysfunction costing approximately $340 billion annually, representing 2.33% of GDP. In the European Union, estimated costs were lower, at approximately $217 billion, or 1.28% of GDP. The authors noted that these differences point to the potential benefits of improved screening for endocrine-disrupting activity and more proactive preventive strategies.

A major driver of the higher U.S. burden was exposure to polybrominated diphenyl ethers (PBDEs). PBDEs are organobromine compounds used as flame retardants in a wide range of products, including building materials, electronics, furnishings, vehicles, aircraft, plastics, polyurethane foams, and textiles. Structurally, PBDEs are similar to polychlorinated biphenyls (PCBs) and other polyhalogenated compounds.

The analysis estimated that PBDE exposure in the United States was associated with a loss of approximately 11 million intelligence quotient (IQ) points and 43,000 cases of intellectual disability, corresponding to an economic cost of $266 billion. In contrast, the European Union was estimated to have lost 873,000 IQ points and experienced 3,290 cases of intellectual disability, with associated costs of $12.6 billion. These findings reflect substantially higher PBDE exposure in the United States compared with Europe.

In the European Union, organophosphate pesticides were identified as the largest contributor to EDC-related disease costs, accounting for approximately $121 billion. In the United States, pesticide-related EDC costs were considerably lower, estimated at $42 billion. This contrast again reflected differences in regulatory approaches and patterns of chemical use.

Overall, the study concluded that endocrine-disrupting chemicals contribute substantially to disease burden and economic costs, with higher impacts observed in regions with greater exposure. The authors suggested that differences between the United States and the European Union highlight the potential value of stronger chemical regulation, improved exposure assessment, and preventive public health strategies aimed at reducing endocrine disruption.